Evidence map›Paper›PMID 38600588›Full record

ArticleCell communication and signaling : CCS2024

VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage.

Hengzhen Li, Yuli Ruan, Chao Liu, Xiaona Fan, Yuanfei Yao, Yisheng Dai, Yushuai Song, Dan Jiang, Ning Sun, Guangtao Jiao and 6 more

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Tumor cell intrinsic mechanisms of immune escape.Cell communication and signaling : CCS · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. CCL20 in the tumor microenvironment: implications for cancer progression and therapeutic approaches.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Hengzhen Li *Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yuli Ruan *Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Chao Liu *Department of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Xiaona FanDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yuanfei YaoDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yisheng DaiDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Yushuai SongDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Dan JiangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Ning SunDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Guangtao JiaoDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Zhuo ChenDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China.
Shiheng FanShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, Shenzhen, China.
Fanfei MengShenzhen Engineering Center for Translational Medicine of Precision Cancer Immunodiagnosis and Therapy, Shenzhen, China.
Huike YangDepartment of Anatomy, Harbin Medical University, Harbin, China. huikeyang@hrbmu.edu.cn.
Yanqiao ZhangDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. yanqiaozhang@ems.hrbmu.edu.cn.
Zhiwei LiDepartment of Gastrointestinal Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China. lizhiwei@hrbmu.edu.cn.
Harbin Medical University · CNThird Affiliated Hospital of Harbin Medical University · CNEducation Department of Heilongjiang Province · CN

Funding

Beijing Medical Award Foundation YXJL-2021-0678-0574Beijing Xisike Clinical Oncology Research Foundation Y-HS2017-033Haiyan Research Fund of Harbin Medical University Cancer Hospital No.JJZD2022-06Heilongjiang Provincial Key R&D Program Projects No. 2022ZX06C10National Natural Science Foundation of China 81773210
6 · The paper itself

Abstract

backgroundActivation of VDR pathway was a promising anti-tumor therapy strategy. However, numerous clinical studies have demonstrated the effect of activating VDR is limited, which indicates that VDR plays a complex role in vivos.

methodsWe analyzed the TCGA database to examine the association between VDR expression and immune cell infiltration in pancreatic adenocarcinoma (PAAD). Western blot, ELISA, ChIP, and dual-luciferase reporter assays were performed to determine the mechanism of VDR regulating CCL20. Migration assay and immunofluorescence were used to investigate the role of CCL20 in M2 macrophage polarization and recruitment. We employed multiplexed immunohistochemical staining and mouse models to validate the correlation of VDR on macrophages infiltration in PAAD. Flow cytometry analysis of M2/M1 ratio in subcutaneous graft tumors.

resultsVDR is extensively expressed in PAAD, and patients with elevated VDR levels exhibited a significantly reduced overall survival. VDR expression in PAAD tissues was associated with increased M2 macrophages infiltration. PAAD cells overexpressing VDR promote macrophages polarization towards M2 phenotype and recruitment in vitro and vivo. Mechanistically, VDR binds to the CCL20 promoter and up-regulates its transcription. The effects of polarization and recruitment on macrophages can be rescued by blocking CCL20. Finally, the relationship between VDR and M2 macrophages infiltration was evaluated using clinical cohort and subcutaneous graft tumors. A positive correlation was demonstrated between VDR/CCL20/CD163 in PAAD tissues and mouse models.

conclusionHigh expression of VDR in PAAD promotes M2 macrophage polarization and recruitment through the secretion of CCL20, which activates tumor progression. This finding suggests that the combination of anti-macrophage therapy may improve the efficacy of VDR activation therapy in PAAD.

Indexed as

AdenocarcinomaChemokine CCL20Pancreatic NeoplasmsReceptors, CalcitriolAnimalsCell Line, TumorHumansMacrophagesMicePhenotypeTumor-Associated MacrophagesTumor MicroenvironmentCCL20 protein, humanChemokine CCL20Receptors, CalcitriolVDR protein, humanCCL20MacrophagePancreatic adenocarcinomaVitamin D receptor

Identifiers

PMID38600588
PMCPMC11005177
OpenAlexW4394689728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.